First AD

Second AD

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Lower-Risk MDS: Current and Future Treatment Strategies

Moffitt Cancer Center

Cancer Centers

Partner

The expert panel reviews updated data from the COMMANDS trial on luspatercept in patients with lower-risk MDS and discusses their effect on clinical practice. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Clinical Insights into the COMMANDS Trial

Myelodysplastic Syndrome: Overview of Diagnosis, Classification, and Treatment

Lower-Risk MDS: How Do Practice Patterns Compare Worldwide?

MEDALIST Trial: Luspatercept in Patients with Lower-Risk MDS

Recent Updates for Second-Line Treatment Options in Lower-Risk MDS

Clinical Implications of Recent Data on New Agents in Lower-Risk MDS

Real-World Data for Luspatercept in Lower-Risk MDS

Treatment Strategies and Sequencing in MDS

Unmet Needs and Future of Lower-Risk MDS